Head-to-head · WeighScore
Hims & Hers vs Found
The verdict
Found takes it — 82/100 to 80/100, but only just.
Found grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aggressive identical pricing on both molecules, wrapped in a coaching-first program. Hims & Hers is close behind and may still be the better fit — see the factor split below.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Hims & Hers | Found |
|---|---|---|
| WeighScore | 80/100 | 82/100 |
| Grade | B− | B− |
| Scorecard rank | #22 | #19 |
| Semaglutide | $199/mo | $129/mo |
| Tirzepatide | Not disclosed | $129/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Editorial | Editorial |
Graded #22 · B−
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Graded #19 · B−
Strengths
- Low identical pricing on both molecules
- Nationwide
- Strong coaching
Where it loses points
- Subscription coaching model isn't for everyone
- Compounded only
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.